It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Varicose veins affect one-third of Western society, with a significant subset of patients developing venous ulceration, costing $14.9 billion annually in the USA. Current management consists of either compression stockings, or surgical ablation for more advanced disease. Most varicose veins patients report a positive family history, and heritability is ~17%. We describe the largest two-stage genome-wide association study of varicose veins in 401,656 individuals from UK Biobank, and replication in 408,969 individuals from 23andMe (total 135,514 cases and 675,111 controls). Forty-nine signals at 46 susceptibility loci were discovered. We map 237 genes to these loci, several of which are biologically plausible and tractable to therapeutic targeting. Pathway analysis identified enrichment in extracellular matrix biology, inflammation, (lymph)angiogenesis, vascular smooth muscle cell migration, and apoptosis. Using a polygenic risk score (PRS) derived in an independent cohort, we demonstrate its predictive utility and correlation with varicose veins surgery.
Although varicose veins are a common condition, the genetic basis is not well understood. Here, the authors find genetic variants associated with varicose veins and show that a higher polygenic risk score for varicose veins correlates with a greater likelihood of patients undergoing surgical treatment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 University of Oxford, Botnar Research Centre, Windmill Road, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
2 Cold Spring Harbor Laboratory, Cold Spring Harbor, USA (GRID:grid.225279.9) (ISNI:0000 0004 0387 3667)
3 23andMe, Inc., Sunnyvale, USA (GRID:grid.420283.f) (ISNI:0000 0004 0626 0858)
4 University of Oxford, John Radcliffe Hospital, Nuffield Department of Surgical Sciences, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492)
5 University of Oxford, John Radcliffe Hospital, Nuffield Department of Women’s & Reproductive Health, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492); University of Oxford, Old Road Campus, Roosevelt Drive, Wellcome Centre for Human Genetics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
6 University of Oxford, Botnar Research Centre, Windmill Road, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Department of Plastic and Reconstructive Surgery, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492)